SSRIs delay ejaculation by flooding the brain and spinal cord with serotonin, a neurotransmitter that acts as a brake on the ejaculatory reflex. This isn’t a rare side effect. Between 25% and 73% of people taking an SSRI experience some form of sexual dysfunction, and delayed ejaculation is one of the most common complaints among men. Understanding why it happens starts with how ejaculation is wired in the nervous system and what serotonin does to that wiring.
How Ejaculation Works in the Nervous System
Ejaculation is a two-phase reflex. The first phase, called emission, moves semen into the urethra through contractions of the vas deferens, seminal vesicles, and prostate. This phase runs on the sympathetic nervous system, using nerve pathways that exit the spinal cord in the lower thoracic and upper lumbar region. The second phase, expulsion, involves rhythmic contractions of the pelvic floor muscles that push semen out of the body.
Both phases are coordinated by a cluster of neurons in the lower spinal cord known as the spinal ejaculation generator. This network integrates signals from the brain, sensory input from the genitals, and output to the muscles and glands involved. It’s essentially the control center for the entire reflex, and it’s heavily regulated by serotonin.
What Serotonin Does to That Reflex
Three serotonin receptor types play direct roles in ejaculation timing. When serotonin activates receptors called 5-HT2C and 5-HT1B, ejaculation is delayed. These receptors sit on neurons in the spinal cord and brain and dampen the excitatory signals that would normally trigger the reflex. When a different receptor type, 5-HT1A, is activated, the opposite happens: it facilitates ejaculation by reducing serotonin release and loosening that inhibitory control.
Under normal conditions, these receptor types balance each other. SSRIs disrupt that balance by blocking the reuptake of serotonin after it’s released into the synapse, the gap between neurons. With reuptake blocked, serotonin lingers longer and accumulates, increasing how much of it reaches 5-HT2C and 5-HT1B receptors. The result is a stronger, more sustained inhibitory signal on the ejaculatory reflex.
Over time, something else happens. With chronic SSRI use, the 5-HT1A autoreceptors (the ones that normally promote ejaculation by dialing serotonin release back down) become desensitized. They stop responding as effectively, which means the system loses its main counterbalance. Serotonin levels stay elevated, and the inhibitory effect on ejaculation becomes even more pronounced. This is why delayed ejaculation often persists or worsens with continued SSRI treatment rather than fading as the body adjusts.
Serotonin Also Suppresses Dopamine
The story doesn’t end with serotonin alone. Dopamine is the neurotransmitter most associated with sexual motivation, arousal, and the motor patterns of sexual behavior. It facilitates ejaculation. Serotonin and dopamine work in opposition in key brain circuits: when serotonin activity goes up, dopamine output goes down.
SSRIs amplify this suppression. Enhanced serotonin signaling through 5-HT1B receptors reduces dopamine release in the mesolimbic pathway, a circuit involved in reward and motivated behavior. This decreases the excitability of the motor neurons responsible for the pelvic muscle contractions of expulsion. So SSRIs don’t just slow the ejaculatory reflex through serotonin. They also weaken the dopamine-driven signals that help push the reflex to completion.
Some SSRIs Also Affect Genital Sensation
Nearly all SSRI users experience some degree of reduced genital sensitivity within 30 minutes of taking a dose. People often describe this as a “numbing” effect. This sensory blunting raises the threshold of stimulation needed to trigger the ejaculatory reflex in the first place, adding a peripheral layer to the delay that sits on top of the central nervous system effects.
One SSRI in particular, paroxetine, has an additional mechanism that goes beyond serotonin. In rat studies, chronic paroxetine treatment reduced the production of nitric oxide in penile tissue by about 61% and decreased the expression of the enzyme that makes nitric oxide by roughly 31%. Nitric oxide is a key chemical messenger for smooth muscle relaxation in the genitals. This effect appears specific to paroxetine and was not seen with other SSRIs like citalopram, which may partly explain why paroxetine is consistently associated with the highest rates of sexual side effects.
Which SSRIs Cause It Most
All SSRIs can cause delayed ejaculation, but the rates vary. In studies comparing sexual dysfunction across different medications, paroxetine consistently ranks worst, with rates between 65% and 71%. Citalopram follows at around 73% for sexual dysfunction broadly (though not all of that is ejaculatory delay specifically). Sertraline causes ejaculatory difficulties in roughly 67% of men, while fluoxetine and fluvoxamine fall in the 54% to 62% range.
For context, bupropion, an antidepressant that works primarily on dopamine and norepinephrine rather than serotonin, causes sexual dysfunction in only about 14% of users. In head-to-head trials, 61% of men on sertraline reported orgasmic dysfunction compared to 10% on bupropion. That stark contrast underscores how central serotonin is to the problem.
When It Starts and Whether It Resolves
The ejaculatory delay begins almost immediately. Genital sensory changes and delayed orgasm can appear within the first dose, though many people notice the effect building over the first one to two weeks as serotonin levels reach a steady state. For most people, these effects lift when the medication is stopped.
In a small subset of users, however, sexual dysfunction persists after discontinuation, a condition now recognized as post-SSRI sexual dysfunction. This can begin after just a few doses or emerge only after years of treatment. Some degree of spontaneous recovery does appear to happen over several years in some cases, but others experience persistent symptoms with only brief, unpredictable remissions.
Managing the Side Effect
If delayed ejaculation becomes a problem during SSRI treatment, dose reduction is usually the first thing to try, though it doesn’t always help. In clinical reports, patients who dropped their sertraline dose from higher levels to 50 mg daily sometimes saw no improvement in sexual function at all.
Adding a second medication is another approach. Buspirone, an anti-anxiety medication, is commonly used off-label alongside SSRIs to counter sexual side effects, with doses typically ranging from 20 to 60 mg daily. Mirtazapine, a different type of antidepressant, has also shown benefit at low doses as an add-on therapy. Both work partly by modulating serotonin receptor activity in ways that soften the inhibitory effects on ejaculation.
Switching to an antidepressant with a different mechanism is sometimes the most effective strategy. Bupropion and nefazodone both carry significantly lower rates of sexual dysfunction. In one trial, 76% of sertraline-treated patients experienced recurrence of ejaculatory or orgasmic difficulty, compared with only 26% of those switched to nefazodone.
Why This Effect Is Used as a Treatment
The same mechanism that causes delayed ejaculation as a side effect has been turned into a treatment for premature ejaculation. Dapoxetine is a short-acting SSRI designed specifically for this purpose. It works the same way as other SSRIs, blocking serotonin reuptake, but it’s absorbed rapidly and has an initial half-life of only about 1.3 to 1.4 hours. That means it can be taken on demand a few hours before sex rather than daily, providing the ejaculatory delay without the sustained serotonin elevation that leads to the broader sexual side effects of long-term SSRI use. Longer-acting SSRIs like sertraline and paroxetine are also sometimes prescribed off-label for premature ejaculation at lower doses, deliberately exploiting the side effect that so many other users find distressing.